■本研究比较了疗效,安全,耐受性,药代动力学(PK),AVT04和参考产品(RP)ustekinumab(Stelara®)在中度至重度慢性斑块状银屑病(PsO)患者中的免疫原性。
■这个多中心,双盲,52周的研究以1:2的比例与AVT04或RP进行随机分组。在第16周,先前接受AVT04治疗的有反应的患者(牛皮癣面积和严重程度指数(PASI)改善≥50%)继续接受AVT04治疗,而接受RP治疗的患者则以1:1的比例重新随机分配以切换至AVT04或继续接受RP治疗。主要终点是PASI从基线到第12周的改善百分比。如果校正后均值差异的置信区间(CI)包含在等效界限内,则证明治疗等效;±10%(90CI)。
■581名最初随机化的患者(AVT04:RP,194:387),575人完成第16周,544人完成研究结束。AVT04与RP的PASI改善百分比为87.3%与86.8%(CI:-2.14%,3.01%);研究达到了主要终点。功效,在整个研究期间,不同治疗组的安全性和PK谱具有可比性,乌司他单抗抗体的发生率没有临床意义.
■该研究证明了AVT04和RP在中度至重度慢性PsO患者中的治疗等效性,具有相似的安全性和耐受性。
■NCT04930042;欧盟编号:2020-004493-22。
This study compared efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity between AVT04 and reference product (RP) ustekinumab (Stelara®) in patients with moderate-to-severe chronic plaque psoriasis (PsO).
This multicenter, double-blind, 52-week study randomized patients in 1:2 ratio to AVT04 or RP. At week 16, responsive patients (≥50% improvement in psoriasis area and severity index (PASI)) previously on AVT04 continued on AVT04, while those on RP were re-randomized 1:1 to switch to AVT04 or stay on RP. The primary endpoint was a percent improvement in PASI from baseline to week 12. Therapeutic equivalence was demonstrated if the confidence interval (CI) for the adjusted difference in means was contained within the equivalence margins; ±10% (90%CI).
Of the 581 patients initially randomized (AVT04:RP, 194:387), 575 completed week 16 and 544 completed end of study visit. The percent PASI improvement for AVT04 vs RP was 87.3% vs 86.8% (CI: -2.14%, 3.01%); study met its primary endpoint. Efficacy, safety and PK profiles were comparable across treatment arms throughout the entire study duration, and the incidence of antibodies to ustekinumab had no clinically meaningful impact.
This study demonstrates the therapeutic equivalence between AVT04 and RP in patients with moderate-to-severe chronic PsO, with similar safety and tolerability.
NCT04930042; EudraCT Number: 2020-004,493-22.